Defunct Company
Total Trials
5
As Lead Sponsor
As Collaborator
0
Total Enrollment
112
NCT03828084
Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 3, 2019
Completion: May 3, 2019
NCT04086238
Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects
Start: Oct 8, 2019
Completion: Nov 30, 2019
NCT04055818
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
Start: Jan 24, 2020
Completion: Apr 30, 2027
NCT05816356
To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males
Start: Mar 24, 2023
Completion: Oct 10, 2023
NCT07006025
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
Start: Jun 3, 2025
Completion: Mar 30, 2027